OncoCyte (OCX)
(Delayed Data from NSDQ)
$2.50 USD
-0.01 (-0.37%)
Updated Apr 23, 2024 11:03 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for OncoCyte Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 8 | 1 | 0 |
Cost Of Goods | 1 | 1 | 8 | 2 | 0 |
Gross Profit | 0 | 0 | 0 | -1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 18 | 74 | 29 | 22 |
Income After Depreciation & Amortization | -25 | -18 | -74 | -30 | -22 |
Non-Operating Income | 0 | -1 | 1 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -19 | -73 | -31 | -22 |
Income Taxes | 0 | 0 | -9 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -19 | -64 | -30 | -22 |
Extras & Discontinued Operations | -3 | -54 | 0 | 0 | 0 |
Net Income (GAAP) | -28 | -73 | -64 | -30 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | 6 | -70 | -27 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 24 | 4 | 3 | 0 |
Income After Depreciation & Amortization | -25 | -18 | -74 | -30 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.65 | 5.54 | 4.45 | 3.27 | 2.57 |
Diluted EPS Before Non-Recurring Items | -4.37 | -3.40 | -7.60 | -9.20 | -8.80 |
Diluted Net EPS (GAAP) | -3.75 | -13.20 | -14.40 | -9.20 | -8.80 |
Fiscal Year end for OncoCyte Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.31 | 0.43 | 0.46 | 0.30 |
Cost Of Goods | NA | 0.43 | 0.18 | 0.19 | 0.29 |
Gross Profit | NA | -0.12 | 0.25 | 0.27 | 0.01 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.07 | 6.77 | 8.57 | -5.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.19 | -6.52 | -8.30 | 5.85 |
Non-Operating Income | NA | 0.35 | -0.09 | -0.04 | 0.12 |
Interest Expense | NA | 0.16 | -0.12 | 0.00 | 0.01 |
Pretax Income | NA | -15.99 | -6.49 | -8.33 | 5.96 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -15.99 | -6.49 | -8.33 | 5.96 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | -2.93 |
Net Income (GAAP) | NA | -15.99 | -6.49 | -8.33 | 3.03 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 8.26 | 8.09 | 5.96 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.57 | -1.07 | -0.80 |
Diluted Net EPS (GAAP) | NA | -2.27 | -0.81 | -1.07 | 0.40 |